![Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis | The BMJ Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis | The BMJ](https://www.bmj.com/content/bmj/375/bmj-2021-066381/F1.medium.jpg)
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis | The BMJ
![What does OS/DFS mean? - Definition of OS/DFS - OS/DFS stands for overall survival and disease-free survival. By AcronymsAndSlang.com What does OS/DFS mean? - Definition of OS/DFS - OS/DFS stands for overall survival and disease-free survival. By AcronymsAndSlang.com](http://acronymsandslang.com/acronym_image/1107/fcf8a23a4ae2aee5ac091263d3778437.jpg)
What does OS/DFS mean? - Definition of OS/DFS - OS/DFS stands for overall survival and disease-free survival. By AcronymsAndSlang.com
![Overall survival by RMH score Hazard Ratio = 2.0 (0.9, 4.6) for 1, 2... | Download Scientific Diagram Overall survival by RMH score Hazard Ratio = 2.0 (0.9, 4.6) for 1, 2... | Download Scientific Diagram](https://www.researchgate.net/publication/321628029/figure/fig1/AS:574529491947521@1513989913838/Overall-survival-by-RMH-score-Hazard-Ratio-20-09-46-for-1-2-vs-0.png)
Overall survival by RMH score Hazard Ratio = 2.0 (0.9, 4.6) for 1, 2... | Download Scientific Diagram
![Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 - Annals of Oncology Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/92cdb022-7df4-45ab-861e-09c65062be4a/gr1_lrg.jpg)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 - Annals of Oncology
![Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of](https://ars.els-cdn.com/content/image/1-s2.0-S0959804914008727-fx1.jpg)
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
![On Biostatistics and Clinical Trials: Understanding the endpoints in oncology: overall survival, progression free survival, hazard ratio, censored value On Biostatistics and Clinical Trials: Understanding the endpoints in oncology: overall survival, progression free survival, hazard ratio, censored value](https://1.bp.blogspot.com/-kUQ4plu5Z10/VetKmGP3SNI/AAAAAAAAAk0/EcsbkS6qlFQ/w1200-h630-p-k-no-nu/image002.gif)
On Biostatistics and Clinical Trials: Understanding the endpoints in oncology: overall survival, progression free survival, hazard ratio, censored value
![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
![Progression-free survival (PFS) curve and overall survival (OS) curve... | Download Scientific Diagram Progression-free survival (PFS) curve and overall survival (OS) curve... | Download Scientific Diagram](https://www.researchgate.net/profile/Shunsuke-Kondo/publication/259989658/figure/fig4/AS:376440932585476@1466761920292/Progression-free-survival-PFS-curve-and-overall-survival-OS-curve-calculated-using.png)
Progression-free survival (PFS) curve and overall survival (OS) curve... | Download Scientific Diagram
![Background - Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? - NCBI Bookshelf Background - Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-methrespfs-lrg.png)
Background - Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? - NCBI Bookshelf
![Overall survival for 648 cases with complete data for MI calculation in... | Download Scientific Diagram Overall survival for 648 cases with complete data for MI calculation in... | Download Scientific Diagram](https://www.researchgate.net/profile/Scott-Hundahl/publication/7452485/figure/fig4/AS:340740170371100@1458250196014/Overall-survival-for-648-cases-with-complete-data-for-MI-calculation-in-the-Dutch-D1-D2_Q320.jpg)
Overall survival for 648 cases with complete data for MI calculation in... | Download Scientific Diagram
![Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study | BMC Cancer | Full Text Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07349-4/MediaObjects/12885_2020_7349_Fig1_HTML.png)
Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study | BMC Cancer | Full Text
![Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study | BMC Cancer | Full Text Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07349-4/MediaObjects/12885_2020_7349_Fig4_HTML.png)
Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study | BMC Cancer | Full Text
![Cumulative incidence of overall survival calculated using Kaplan-Meier... | Download Scientific Diagram Cumulative incidence of overall survival calculated using Kaplan-Meier... | Download Scientific Diagram](https://www.researchgate.net/publication/327430144/figure/fig1/AS:667311556026370@1536110881455/Cumulative-incidence-of-overall-survival-calculated-using-Kaplan-Meier-survival-analysis.png)
Cumulative incidence of overall survival calculated using Kaplan-Meier... | Download Scientific Diagram
![Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11060-017-2619-1/MediaObjects/11060_2017_2619_Fig1_HTML.gif)